Acquired Hypertrichosis Lanuginosa: 3 Key Management Strategies
Rare paraneoplastic condition causing rapid fine lanugo hair growth, often signaling underlying malignancy.
Acquired hypertrichosis lanuginosa, also known as hypertrichosis lanuginosa acquisita (HLA), is a rare dermatological condition characterized by the sudden appearance of fine, soft, unpigmented lanugo-type hairs, predominantly on the face but potentially extending to other areas. This paraneoplastic syndrome often signals an underlying internal malignancy, necessitating urgent medical evaluation.
What is acquired hypertrichosis lanuginosa?
**Acquired hypertrichosis lanuginosa** involves the rapid proliferation of lanugo hairs—fine, downy hairs typically seen in fetuses and newborns—appearing later in life, distinguishing it from congenital forms. Unlike typical vellus or terminal hairs, these are thin, elongated (up to several centimeters), and hypopigmented, creating a striking ‘moth-eaten’ or ‘dog-ear’ appearance around the eyes, nose, and ears. The condition primarily affects adults aged 40-70, with a marked female predominance.
While the face is most commonly involved, extensive cases may cover the trunk, axillae, and extremities, sparing palms, soles, scalp, and mucous membranes. Hairs emerge symmetrically, growing at an accelerated rate of up to 1.5 cm per month, often within weeks to months. This differentiates it from other hypertrichoses, such as drug-induced or localized forms.
Who gets acquired hypertrichosis lanuginosa?
HLA predominantly affects middle-aged to elderly women, with over 80% of reported cases in females aged 40-70 years. It is exceedingly rare, with fewer than 100 cases documented worldwide, underscoring its paraneoplastic nature. Risk factors include a history of smoking or exposure to carcinogens, given associations with lung and colorectal cancers. Non-malignant cases are even rarer, linked to conditions like HIV/AIDS or severe malnutrition.
What causes acquired hypertrichosis lanuginosa?
The precise etiology remains elusive, but HLA is postulated to result from tumor-secreted substances or hormones stimulating hair follicle reactivation. In over 90% of cases, it is paraneoplastic, preceding, coinciding with, or following malignancy diagnosis by up to 2 years.
Associated malignancies include:
- Lung cancer (most common, ~25% of cases)
- Colorectal cancer (~20%)
- Breast cancer (~15%)
- Uterine/ovarian cancer
- Lymphoma and bladder cancer
Less commonly, non-neoplastic triggers encompass drugs (e.g., ciclosporin, phenytoin, spironolactone, corticosteroids), hyperthyroidism, anorexia nervosa-induced malnutrition, and HIV/AIDS. These may mimic oncogene activation pathways, promoting ectopic lanugo growth.
What are the clinical features of acquired hypertrichosis lanuginosa?
The hallmark is rapid-onset, symmetrical lanugo hair growth, fine and colorless, framing the face like ‘eyelash extensions’ or ‘bearded lady’ tufts. Hairs measure 1-3 cm, occasionally longer, with a soft, wavy texture.
| Common Sites | Description |
|---|---|
| Face (periorbital, nasal, auricular) | Primary; dense mats around eyes, nose, ears |
| Trunk & extremities | Extensive cases; axillae, forearms |
| Sparing areas | Palms, soles, scalp, genitals |
Associated
paraneoplastic signs
heighten suspicion:- Glossitis: Burning, enlarged tongue with papillary hypertrophy
- Sensory changes: Dysgeusia (taste distortion), hyposmia (smell loss)
- Gastrointestinal: Diarrhea, weight loss
- Lymphadenopathy: Enlarged glands
- Cutaneous: Acquired ichthyosis, acanthosis nigricans, tripe palms, Leser-Trélat sign (sudden seborrheic keratoses)
Systemic symptoms like cachexia or anorexia often accompany advanced malignancy.
How is acquired hypertrichosis lanuginosa diagnosed?
Diagnosis relies on clinical pattern recognition, prompting exhaustive malignancy workup. Dermoscopy reveals uniform fine hairs without follicles distortion. Biopsy, if performed, shows normal hair follicles with increased lanugo production, excluding tumors. Diagnostic algorithm: HLA may precede cancer detection, warranting serial screening. Treatment targets the underlying cause; hair regresses post-malignancy therapy in ~50% of cases. No specific therapy exists for HLA itself. Management strategies: Prognosis correlates with malignancy stage; early detection via HLA improves outcomes. A: No, ~90-95% associate with malignancy, but drugs, malnutrition, HIV, or thyroid disease can cause it. A: Rapidly, up to 1.5 cm/month, appearing over weeks. A: Temporary reduction possible, but recurrence common until underlying cause resolves. A: Lung, colorectal, breast, uterine, lymphoma. A: Extremely rare; adult-onset paraneoplastic.
What is the treatment for acquired hypertrichosis lanuginosa?
Frequently asked questions about acquired hypertrichosis lanuginosa
Q: Is acquired hypertrichosis lanuginosa always cancer?
Q: How quickly does the hair grow?
Q: Can laser remove the hair permanently?
Q: What cancers are most linked?
Q: Does it affect children?
Related topics
References
Similar Articles
Read full bio of medha deb
